Biologics and Biosimilars in Multiple Sclerosis
In this video, Dr. Boster discusses the use of Biologics and Biosimilars in Multiple Sclerosis. Visit the MS Views and…
What Is a Wash-Out Period? 8 Things To Know for DMTs (Disease Modifying Therapies)
Written by Maureen McNulty Medically reviewed by Luc Jasmin, M.D., Ph.D., FRCS (C), FACS If you have multiple sclerosis (MS) and want…
Stuart Schlossman
Vanda acquires rights to Ponvory for MS in US, Canada for $100M
by Patricia Inacio, PhD | December 12, 2023 Oral therapy approved in both countries to lower relapse rates Vanda Pharmaceuticals has acquired the U.S.…
Stuart Schlossman
Evobrutinib is no better than teriflunomide
The EVOLUTION phase 3 clinical trials showed evobrutinib did not meet its primary endpoint of annualized relapse rate for up…
Stuart Schlossman
video: Biomarkers and Biosimilars for MS — an MS Views NOW event
https://bit.ly/3SOafcO Stay informed with MS information, news and resources. Sign-up Here: https://bit.ly/3NkMIeR Visit the MS Views and News articles and videos…
Stuart Schlossman
New Data Shows Positive Efficacy and Safety Outcomes After 10 Years of Ocrevus Treatment
October 18, 2023 Rosanna Sutherby, Pharm.D. In 2017, the FDA approved Genentech’s Ocrevus (ocrelizumab) for the treatment of relapsing forms…
Stuart Schlossman
Intranasal Foralumab for Multiple Sclerosis Now Approved by FDA for At-Home Dosing
October 20, 2023 Isabella Ciccone, M.P.H. The FDA’s decision to allow at-home dosing of intransal foralumab for patients with multiple…
Stuart Schlossman
S1P Receptor Modulator May Boost Cognitive Processing Speed in Early MS
Ozanimod (Zeposia) led to test score improvements in interim analysis by Judy George, Deputy Managing Editor, MedPage Today October 19, 2023 Share…
Stuart Schlossman
BTK Inhibitor Reduces Brain Lesions in Relapsing MS
— Subgroup analysis shows brain penetration by Judy George, Deputy Managing Editor, MedPage Today October 19, 2023 Share on Facebook. Opens…
Stuart Schlossman
PRESS RELEASE: Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions
Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over…
Stuart Schlossman
